Galderma Seizes Opportunity in Weight Loss Drug Market with New Fillers for ‘Ozempic Face'”.

As a Swiss pharmaceutical company known for its skin care treatments, Galderma has recognized an opportunity in the growing popularity of weight-loss drugs like Ozempic. The CEO believes that the demand for their facial fillers products may increase as patients seek to counteract the sunken-in look that can result from using Ozempic.

Galderma has products such as Sculptra and Restylane that are designed to restore the gaunt look associated with Ozempic face. In fact, the company is currently conducting a study to evaluate the effects of these products for cheek augmentation and contour deficiencies in patients using GLP-1 treatments. Enrollment is ongoing, and results may be available by the end of the year.

Dermatologists have noted that “Ozempic face” has become increasingly common in their practices due to the widespread use of weight-loss medications. This term refers to the sunken and aged appearance that can result from rapid weight loss. However, Galderma’s filler products can help patients achieve a more youthful appearance, which may be particularly appealing to those who are concerned about their overall health and wellness.

In addition to its filler products, Galderma also owns popular drug store brand Cetaphil. The CEO remains optimistic about the growth potential in the fillers market and plans to capitalize on the trend of weight-loss drugs like Ozempic by expanding its product offerings and targeting new markets.